Aim: Recombinant human thyroid-stimulating hormone (rhTSH) recently was approved as an alternative to thyroid hormone withholding (THW) to elevate TSH for thyroid remnant ablation in differentiated thyroid carcinoma patients. High ablation success rates are reported with diverse rhTSH-aided (131)I activities. Improved renal function causes approximately 50% faster radioiodine clearance under euthyroidism versus hypothyroidism. Knowledge of comparative remnant radioiodine kinetics, particularly the remnant radiation dose in Gy/GBq of administered (131)I activity (RDpA), could assist in choosing rhTSH-aided ablative activities.
Material And Methods: To compare the RDpA, determined through (124)I-positron emission tomography/computed tomography (PET/CT), under the two stimulation methods, we retrospectively divided into two groups 55 consecutive totally-thyroidectomized, radioiodine-naïve patients. The rhTSH group (n=16) received (124)I on thyroid hormone, 24 h after two consecutive daily intramuscular injections of rhTSH, 0.9 mg. The THW group (n=39) received (124)I after weeks-long THW, when serum TSH first measured > or = 25 mIU/L. We performed PET investigations 4 h, 24 h, 48 h, 72 h and 96 h and PET/CT 25 h after (124)I administration.
Results: Median stimulated serum thyroglobulin was 15 times higher (p=0.023) and M1 disease almost twice as prevalent (p=0.05) in rhTSH versus THW patients. Mean+/-standard deviation RDpA was statistically equivalent between the groups: rhTSH, 461+/-600 Gy/GBq, THW, 302+/-329 Gy/GBq, two-sided p=0.258.
Conclusions: rhTSH or THW deliver statistically equivalent radiation doses to thyroid remnant and may be chosen based on safety, quality-of-life, convenience and pharmacoeconomic factors. Institutional fixed radioiodine activities formulated for use with THW need not be adjusted for rhTSH-aided ablation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0029-1225350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EFFICACY AND PROGNOSIS IN PATIENTS WITH PAPILLARY THYROID CANCER WITH POSTOPERATIVE PREABLATIVE STIMULATED THYROGLOBULIN ABOVE 10 NG/ML AFTER INITIAL THERAPY WITH RADIOIODINE.
Acta Endocrinol (Buchar)
January 2025
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China - Department of Nuclear Medicine, Hefei, Anhui, China.
Objective: Few prognostic analyses have been conducted for papillary thyroid cancer (PTC) patients with preablative stimulated Tg >10 ng/mL. We investigated the therapeutic responses and prognosis of these patients after the initial radioiodine (RAI) therapy.
Methods: We retrospectively assessed 256 patients with PTC who underwent RAI remnant ablation after total thyroidectomy, and all presTg levels were >10 ng/mL.
Extent of Surgery in the Surgical Treatment of Graves' Disease: Subtotal vs. Total Thyroidectomy and Comparison of the Long-term Results.
Sisli Etfal Hastan Tip Bul
December 2024
Department of General Surgery, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye.
Objectives: The extent of the surgical treatment for Graves' disease (GD) has evolved from subtotal to total thyroidectomy. This study analyzes the extent of thyroidectomy for GD and its impact on recurrence and complications, focusing on the relationship between remnant thyroid tissue and recurrence in subtotal thyroidectomy, comparing our current approach with historic data spanning over three decades.
Methods: A retrospective analysis of 427 GD patients who underwent surgery at a tertiary hospital from 1988 to 2022.
Introduction: Differentiated thyroid cancer (DTC) is the most common type of endocrine malignancy, with rising incidence over recent decades. Despite a favorable prognosis, DTC management remains complex, often involving thyroidectomy followed by radioactive iodine (RAI) therapy. While RAI is crucial for patient outcomes, its efficacy varies, necessitating the identification of predictors for treatment response.
View Article and Find Full Text PDFRadiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis.
J Neurooncol
January 2025
Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Background: Craniopharyngioma (CP), a benign tumor originating from remnants of Rathke's pouch in the sellar region, accounts for approximately 30% of all cases of craniopharyngioma. Radiation therapy has been used to treat CP patients for decades; however, there is still a lack of systematic reviews on the long-term tumor control outcomes in pediatric CP patients treated with external radiation therapy.
Methods: We conducted a comprehensive search of multiple databases for studies on the tumor progression rates of childhood-onset CP(COCP) patients who received external radiotherapy.
Radioactive Iodine Treatment for Thyroid Cancer Complicated by Lacrimal Sac Retention of Iodine.
JCEM Case Rep
January 2025
Division of Endocrinology, Medstar Georgetown University Hospital, Washington, DC 20007, USA.
Patients with intermediate-risk thyroid cancers may undergo treatment with radioactive iodine-131 (I-131). They often undergo a pretreatment diagnostic iodine scan that typically shows areas of physiological uptake in the stomach, bladder, parotid glands as well as thyroid-remnant uptake and sites of metastatic disease. A 48-year-old woman with intermediate-risk papillary thyroid cancer with metastases to lateral compartment lymph nodes was found to have increased retention of iodine in the medial portion of her left orbit on the diagnostic scan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!